key: cord-0014628-75vknf0m
authors: Piorecka, Kinga; Kurjata, Jan; Stanczyk, Wlodzimierz A.
title: Novel Polyhedral Silsesquioxanes [POSS(OH)(32)] as Anthracycline Nanocarriers—Potential Anticancer Prodrugs
date: 2020-12-24
journal: Molecules
DOI: 10.3390/molecules26010047
sha: 3f89efc4d8ba183257871f8f47f4201d8ffb9735
doc_id: 14628
cord_uid: 75vknf0m

Anthracyclines belong to the anticancer drugs that are widely used in chemotherapy. However, due to their systemic toxicity they also exert dangerous side effects associated mainly with cardiovascular risks. The pathway that is currently often developed is their chemical and physical modification via formation of conjugated or complexed prodrug systems with a variety of nanocarriers that can selectively release the active species in cancer cells. In this study, six new nanoconjugates were synthesized with the use of polyhedral oligosilsesquioxanes [POSS(OH)(32)] as nanocarriers of the anticancer drugs anthracyclines—doxorubicin (DOX) and daunorubicin (DAU). These prodrug conjugates are also equipped with poly(ethylene glycol) (PEG) moieties of different structure and molecular weight. Water-soluble POSS, succinic anhydride modified (SAMDOX and SAMDAU) with carboxylic function, and PEGs (PEG1, PEG2 and PEGB3) were used for the synthesis. New nanoconjugates were formed via ester bonds and their structure was confirmed by NMR spectroscopy ((1)H-NMR, (13)C-NMR, (1)H-(13)C HSQC, DOSY and (1)H-(1)H COSY), FTIR and DLS. Drug release rate was evaluated using UV-Vis spectroscopy at pH of 5.5. Release profiles of anthracyclines from conjugates 4–9 point to a range of 10 to 75% (after 42 h). Additionally, model NMR tests as well as diffusion ordered spectroscopy (DOSY) confirmed formation of the relevant prodrugs. The POSS-anthracycline conjugates exhibited prolonged active drug release time that can lead to the possibility of lowering administered doses and thus giving them high potential in chemotherapy. Drug release from conjugate 7 after 42 h was approx. 10%, 33% for conjugate 4, 47% for conjugate 5, 6, 8 and 75% for conjugate 9.

We are currently witnessing a rapid development of anticancer drug delivery systems [1, 2] , exploiting such nanocarriers as, e.g., gold and mesoporous silica nanoparticles, polymers, and dendrimers [3] . Nanotechnology and nanomedicine [4, 5] now offer a variety of systems that are intensively studied as delivery vehicles, modulating cytotoxicity and mediating sustained drug release in tumour tissues.

Anthracycline chemotherapy with antibiotics such as doxorubicin (DOX) and daunorubicin (DAU) plays an important role in treating many types of cancer. They exhibit wide action spectrum, high efficacy and are used in the form of soluble hydrochlorides.

They intercalate with DNA, inhibiting proliferation of cancer cells and leading to their apoptosis. Unfortunately, they are not selective and administration of high doses can often lead to heart failure [6] . Nanotechnology is one of the ways to increase the selectivity of chemotherapy via limiting systemic toxicity. The use of nanoparticles has been shown to improve the selective transport of drugs and their accumulation in the tumour, which in turn can lead to dose reduction [7] . Encapsulation, complexation or conjugation of these drugs with nanocarriers leads to slow release of the active drug, extending its time of action, leading to decreased doses. Our previous studies have been devoted to the use of polyhedral oligosilsesquioxanes as nanocarriers of anti-cancer drugs [8] [9] [10] [11] . Silsesquioxanes are well known to facilitate cell membrane penetration [12] , an important feature in drug delivery. Additionally, they are biocompatible [13] and nontoxic [14] . The current research presents results on application of hydrophilic silsesquioxanes, known in the literature as [POSS (OH) 32 ], as novel anthracycline nanocarriers, synthesized by hydrolytic condensation of a functionalized precursor-N,N-di(2,3-dihydroxypropyl)(aminopropyl)triethoxysilane [15] . Contrary to the previously used POSSs, the silsesquioxanes obtained from N,N-di(2,3-dihydroxypropyl)(aminopropyl)triethoxysilane have relatively narrow size distribution and a large number of functional OH moieties. The average particle diameter of these water soluble structures is on average~3.0 nm and the synthesis of such a system is simple and effective. Additionally, due to partial coupling of hydroxyl groups of the carrier with carboxy terminated, methoxylated poly(ethylene glycol) (PEG), apart from esterification with succinic anhydride modified anthracyclines [16] , the solubility in aqueous media can be largely improved. It also allows additional binding of the targeting moiety biotin (Figures 1 and 2) .

action, leading to decreased doses. Our previous studies have been devoted to the use polyhedral oligosilsesquioxanes as nanocarriers of anti-cancer drugs [8] [9] [10] [11] . Silsesqui anes are well known to facilitate cell membrane penetration [12] , an important feature drug delivery. Additionally, they are biocompatible [13] and nontoxic [14] . The curr research presents results on application of hydrophilic silsesquioxanes, known in the erature as [POSS(OH)32], as novel anthracycline nanocarriers, synthesized by hydroly condensation of a functionalized precursor-N,N-di(2,3-dihydroxypropyl)(aminop pyl)triethoxy-silane [15] . Contrary to the previously used POSSs, the silsesquioxanes o tained from N,N-di (2,3-dihydroxypropyl) (aminopropyl)triethoxysilane have relativ narrow size distribution and a large number of functional OH moieties. The average p ticle diameter of these water soluble structures is on average ~3.0 nm and the synthesis such a system is simple and effective. Additionally, due to partial coupling of hydro groups of the carrier with carboxy terminated, methoxylated poly(ethylene glycol) (PE apart from esterification with succinic anhydride modified anthracyclines [16] , the so bility in aqueous media can be largely improved. It also allows additional binding of targeting moiety biotin (Figures 1 and 2) . (7), daunorubicin and PEG2-PossDauPEG2 and daunorubicin and PEGB3-PossDauPEGB3 (9) (Figure 2 ). The research was aimed develop effective synthetic methods of silsesquioxane nanoconjugates with antican drugs. Such conjugates would be capable of releasing active drugs in cancer cells. T structure of all synthesized nanoconjugates was confirmed by NMR spectroscopy, FT and DLS. 

The model reaction (Figures S2 and S3 and Table S1 ) was carried out to allow interpretation of complex NMR spectra of nanoconjugates (4) (5) (6) (7) (8) (9) . The POSS structure-T 8 [(CH 2 ) 2 S(CH 2 ) 2 OH] 8 applied in the model reaction has a well-defined structure, in contrast to [POSS(OH) 32 ] being a mixture of cage silsesquioxanes. It was obtained by modifying commercial POSS-Vi with 2-mercapotetanol. In addition, PEG1 with a lower molecular weight was used, which simplifies interpretation of the NMR spectra. The post reaction mixture was pre-purified (see Section 3), and its composition was determined using 1 H-1 H COSY and 1 H-13 C HSQC NMR spectra of the substrates and the product. Thus, in the subsequent syntheses, it was possible to determine whether the purified products also contained free drugs and/or free PEGs.

Total drug content was measured using UV-Vis spectroscopy ( Figure 3 ). Nanoconjugates (4-9) (1 mg) were dissolved in H 2 O/DMF (1 mL, 5:1), then 200 µL of this solution was taken and diluted with 3 mL of solvent (H 2 O/DMF (5:1)), followed by mixing with 0.2 mL HCl (36%). It was kept at 50 • C for 2 h and then at room temperature for 24 h. A calibration curve for DOX/DAU was constructed and total drug content was calculated from UV-Vis spectra of DOX, DAU and all the nanoconjugates (4-9) at 480 nm ( Figures S4 and S5 ).

The model reaction (Figures S2 and S3 and Table S1 ) was carried out to allow interpretation of complex NMR spectra of nanoconjugates (4) (5) (6) (7) (8) (9) . The POSS structure-T 8 [(CH2)2S(CH2)2OH]8 applied in the model reaction has a well-defined structure, in contrast to [POSS(OH)32] being a mixture of cage silsesquioxanes. It was obtained by modifying commercial POSS-Vi with 2-mercapotetanol. In addition, PEG1 with a lower molecular weight was used, which simplifies interpretation of the NMR spectra. The post reaction mixture was pre-purified (see Section 3), and its composition was determined using 1 H-1 H COSY and 1 H-13 C HSQC NMR spectra of the substrates and the product. Thus, in the subsequent syntheses, it was possible to determine whether the purified products also contained free drugs and/or free PEGs.

Total drug content was measured using UV-Vis spectroscopy ( Figure 3 ). Nanoconjugates (4-9) (1 mg) were dissolved in H2O/DMF (1 mL, 5:1), then 200 µL of this solution was taken and diluted with 3 mL of solvent (H2O/DMF (5:1)), followed by mixing with 0.2 mL HCl (36%). It was kept at 50 °C for 2 h and then at room temperature for 24 h. A calibration curve for DOX/DAU was constructed and total drug content was calculated from UV-Vis spectra of DOX, DAU and all the nanoconjugates (4-9) at 480 nm ( Figures S4  and S5 ). Table 1 shows that conjugate 4 (42.88%) has the highest anthracycline content and conjugate 6 (16.38%) the lowest. Conjugate 4 (88.0%) exhibits the highest efficiency of drug attachment, while conjugate 5 is characterized by the lowest (47.4%). The PEG1-containing conjugates (4 and 7) are most effective in conjugation with anthracyclines. In contrast, the conjugates containing PEGB3 in the molecule show the lowest efficiency of binding drugs. This may be related to the molecular mass and structure of PEGs-PEGB3 has the highest molecular mass, thus slowing down the ester bond formation. Intensity Wavelength (nm) Table 1 shows that conjugate 4 (42.88%) has the highest anthracycline content and conjugate 6 (16.38%) the lowest. Conjugate 4 (88.0%) exhibits the highest efficiency of drug attachment, while conjugate 5 is characterized by the lowest (47.4%). The PEG1-containing conjugates (4 and 7) are most effective in conjugation with anthracyclines. In contrast, the conjugates containing PEGB3 in the molecule show the lowest efficiency of binding drugs. This may be related to the molecular mass and structure of PEGs-PEGB3 has the highest molecular mass, thus slowing down the ester bond formation. 

DOX/DAU release from the nanoconjugates was determined in citrate buffer solution-(pH 5.5 0.1 M) at 310 K. Nanoconjugates, dissolved in DMF, were placed in a dialysis bag (MWCO: 2 kD, Spectrum Laboratories) and inserted into buffer solution (conjugate concentrations are described in the Table S3 ). The amount of released drug was calculated from the UV-Vis spectra. The drug release profile of PossDauPEGB3 (9) conjugate showed the fastest release of DAU in an acid environment. In this case, over 60% of POSS conjugated DAU was released within 21 h and over 70% within 42 h. Release profiles of anthracyclines from conjugates 4-6 and 8 point to a maximum amount after 42 h in the range of 33 to 47%. Conjugate 7 showed the lowest drug release profile (only~10% after 21 h and 42 h). As can be seen in Figure 4 , the drug release profiles from the conjugates with PEG1 indicate the lowest release values, and are not dependent only on the type of applied PEG. It can be also related to the complexation of drugs and PEGs (not covalently bound to POSS). Conjugate 9 has a biotynyl fragment that can form drug complexes with NH moieties via hydrogen bonds. Non-covalent systems involving anthracyclines are known to be formed and are cleaved easier than relevant conjugates [1] . The hydrogen bonded anthracyclines and POSS(OH) 32 complexes have been recently described [17] . Additionally, Figure S6 shows the graphs of absorbance intensity measured with UV-Vis for drug release from the relevant conjugates after 21 h and 42 h. It is evident that the drug release rate from conjugates is slow enough to make them potentially good candidates for anti-cancer therapy [17] . 

DOX/DAU release from the nanoconjugates was determined in citrate buffer solution-(pH 5.5 0.1 M) at 310 K. Nanoconjugates, dissolved in DMF, were placed in a dialysis bag (MWCO: 2 kD, Spectrum Laboratories) and inserted into buffer solution (conjugate concentrations are described in the Table S3 ). The amount of released drug was calculated from the UV-Vis spectra. The drug release profile of PossDauPEGB3 (9) conjugate showed the fastest release of DAU in an acid environment. In this case, over 60% of POSS conjugated DAU was released within 21 h and over 70% within 42 h. Release profiles of anthracyclines from conjugates 4-6 and 8 point to a maximum amount after 42 h in the range of 33 to 47%. Conjugate 7 showed the lowest drug release profile (only ~10% after 21 h and 42 h). As can be seen in Figure 4 , the drug release profiles from the conjugates with PEG1 indicate the lowest release values, and are not dependent only on the type of applied PEG. It can be also related to the complexation of drugs and PEGs (not covalently bound to POSS). Conjugate 9 has a biotynyl fragment that can form drug complexes with NH moieties via hydrogen bonds. Non-covalent systems involving anthracyclines are known to be formed and are cleaved easier than relevant conjugates [1] . The hydrogen bonded anthracyclines and POSS(OH)32 complexes have been recently described [17] . Additionally, Figure S6 shows the graphs of absorbance intensity measured with UV-Vis for drug release from the relevant conjugates after 21 h and 42 h. It is evident that the drug release rate from conjugates is slow enough to make them potentially good candidates for anticancer therapy [17] . As the plots in Figure 4 prove, the conjugates (4 and 7) containing PEG1 in their structure show the slowest rate release of the drugs, while the PEG2-containing conjugates show higher and similar release profiles. This may originate from the fact that drug content in 4 and 7 is the highest amongst all the synthesized systems.

Basing on the 1 H-13 C HSQC spectra, we were able to confirm the formation of ester bonded conjugates. Figure 5 shows the 1 H-13 C HSQC spectra of the conjugates superimposed on the spectra of the substrates (PEG and POSS). It points to differences in proton shift values associated with ester bond formation. The PEG1 protons chemical shift (CH 2 COOH) moved towards the lower field (from 2.38 to 2.53 ppm for conjugate 4 and from 2.38 to 2.45 ppm for conjugate 7) on formation of the ester bonds. The PEG2 protons chemical shift (CH 2 COOH) also changed towards the lower field from~2.4 to~2.5 ppm for conjugates 5 and 8. The same also applies to PEGB3 (a shift from 2.39 to 2.53 ppm for conjugate 6 and from 2.39 to 2.50 ppm for conjugate 9). In order to investigate differences in chemical shifts of POSS before and after ester bond formation, POSS spectra were superimposed on the conjugates spectra. Based on the spectra, it can be concluded that in conjugates 4, 6 and 9, there is incomplete substitution of the hydroxyl groups. This is evidenced by additional cross peaks at the chemical shift values overlapping with the POSS (-CH 2 OH) proton shift values −3.29-3.35 ppm. As the plots in Figure 4 prove, the conjugates (4 and 7) containing PEG1 in their structure show the slowest rate release of the drugs, while the PEG2-containing conjugates show higher and similar release profiles. This may originate from the fact that drug content in 4 and 7 is the highest amongst all the synthesized systems.

Basing on the 1 H-13 C HSQC spectra, we were able to confirm the formation of ester bonded conjugates. Figure 5 shows the 1 H-13 C HSQC spectra of the conjugates superimposed on the spectra of the substrates (PEG and POSS). It points to differences in proton shift values associated with ester bond formation. The PEG1 protons chemical shift (CH2COOH) moved towards the lower field (from 2.38 to 2.53 ppm for conjugate 4 and from 2.38 to 2.45 ppm for conjugate 7) on formation of the ester bonds. The PEG2 protons chemical shift (CH2COOH) also changed towards the lower field from ~2.4 to ~2.5 ppm for conjugates 5 and 8. The same also applies to PEGB3 (a shift from 2.39 to 2.53 ppm for conjugate 6 and from 2.39 to 2.50 ppm for conjugate 9). In order to investigate differences in chemical shifts of POSS before and after ester bond formation, POSS spectra were superimposed on the conjugates spectra. Based on the spectra, it can be concluded that in conjugates 4, 6 and 9, there is incomplete substitution of the hydroxyl groups. This is evidenced by additional cross peaks at the chemical shift values overlapping with the POSS (-CH2OH) proton shift values −3.29-3.35 ppm. Figure 6 shows the superimposed 1 H-13 C HSQC spectra of the conjugates on the SAMDOX and SAMDAU spectra to investigate differences in chemical shifts of the anthracycline protons adjacent to the ester/carboxylic functions after (red) and before (green-SAMDOX and SAMDAU) the conjugation. The formation of an ester bond is associated with a change in the chemical shifts of adjacent protons (POSS-antracycline-CH2CH2-ester bond) towards the lower field. For conjugates 5 and 8 containing PEG2 in their molecule, this is a marked change from ~2.3 ppm to ~2.5 ppm. In contrast to the 1 H-13 C HSQC spectra shown after superimposing PEG/POSS on the spectra of the conjugates (Figure 5) , the 1 H-13 C HSQC spectra ( Figure 6 ) did not give an unequivocal answer as to whether SAMDOX and SAMDAU are incorporated into the product. Figure 6 shows the superimposed 1 H-13 C HSQC spectra of the conjugates on the SAM-DOX and SAMDAU spectra to investigate differences in chemical shifts of the anthracycline protons adjacent to the ester/carboxylic functions after (red) and before (green-SAMDOX and SAMDAU) the conjugation. The formation of an ester bond is associated with a change in the chemical shifts of adjacent protons (POSS-antracycline-CH 2 CH 2 -ester bond) towards the lower field. For conjugates 5 and 8 containing PEG2 in their molecule, this is a marked change from~2.3 ppm to~2.5 ppm. In contrast to the 1 H-13 C HSQC spectra shown after superimposing PEG/POSS on the spectra of the conjugates (Figure 5) , the 1 H-13 C HSQC spectra ( Figure 6 ) did not give an unequivocal answer as to whether SAMDOX and SAMDAU are incorporated into the product. 

Diffusion NMR spectroscopy (DOSY) was performed to further confirm the formation of the conjugates 4-9. The results were determined by superimposing the DOSY spectra of the substrates (SAMDOX/SAMDAU, PEG1/PEG2/PEGB3 and POSS(OH)32) on the DOSY spectrum of the products (conjugates 4-9) (Figure 7) . Self-diffusion coefficients 

Diffusion NMR spectroscopy (DOSY) was performed to further confirm the formation of the conjugates 4-9. The results were determined by superimposing the DOSY spectra of the substrates (SAMDOX/SAMDAU, PEG1/PEG2/PEGB3 and POSS(OH) 32 ) on the DOSY spectrum of the products (conjugates 4-9) (Figure 7) . Self-diffusion coefficients (D) of the SAMDOX, SAMDAU, POSS(OH) 32 , PEG1, PEG2, PEGB3 and conjugates 4-9 were determined from the resonance signals: POSS (1.45 ppm), SAMDOX (7.84 ppm), SAMDAU (7.79 Figure 8 . Differences in diffusion rates of substrates and conjugates (4-9) point to the formation of larger conjugated molecules, as they migrate at a smaller rate than the relevant substrates, due to a lower value of self-diffusion coefficients. 

FTIR spectroscopy was additionally used for structural characterization of the conjugates formed via ester bond between drugs and the POSS carrier. FTIR spectra of conjugates differed from that of SAMDOX/SAMDAU [11] . The spectra of conjugates 4-9 ( Figure  9 ) show a new absorption frequency at ~1734 cm −1 (νC=O, ester bond) indicating formation of an ester bond between SAMDOX/SAMDAU and the POSS hydroxyl groups. 

FTIR spectroscopy was additionally used for structural characterization of the conjugates formed via ester bond between drugs and the POSS carrier. FTIR spectra of conjugates differed from that of SAMDOX/SAMDAU [11] . The spectra of conjugates 4-9 ( Figure 9 ) show a new absorption frequency at~1734 cm −1 (ν C=O , ester bond) indicating formation of an ester bond between SAMDOX/SAMDAU and the POSS hydroxyl groups. Conjugate 4 ( Figure 10A ) exhibits the new absorption band at 1732 cm −1 (ν C=O , ester bond), clearly indicating the formation of ester bond between SAMDOX/PEG1 and POSS(OH) 32 . There is no absorption in the spectrum indicating the presence of unreacted carboxyl groups (SAMDOX 1721 cm −1 (ν C=O carboxylic bond) and PEG1 1722 cm −1 (ν C=O carboxylic bond)). The same characteristic absorption is also evident for conjugate 6 ( Figure 10C ). 

The hydrodynamic diameter of the POSS(OH)32 and conjugates 4-9 was investigated by DLS. Figure 11 shows that POSS has the highest hydrodynamic diameter, which may suggest that its hydroxyl groups form a network of hydrogen bonds. The involvement of The spectrum of conjugate 5 ( Figure 10B ) is more difficult to interpret as PEG2 also has an ester linkage. We can assume that the ester bond in conjugate 5 has been formed, as shown by the shift of the ν C=O PEG2 (ester bond) absorption from 1732 cm −1 to 1734 cm −1 . There is no absorption in the spectrum that would indicate the presence of unreacted carboxyl groups. The same conclusion can be drawn from the spectrum of conjugate 8 ( Figure 10E ).

In contrast, in the spectrum of conjugate 7 ( Figure 10D) , the absorption at 1732 cm −1 (ν C=O ester bond), indicating the formation of ester bond, also appears, but there are still unreacted carboxyl groups from SAMDAU or PEG1 as shown by widening of the band at 1732 cm −1 . The situation is similar for conjugate 9 ( Figure 10F ), however, here there is a clear absorption at 1708 cm −1 indicating unreacted -COOH moieties from SAMDAU or PEGB3.

The hydrodynamic diameter of the POSS(OH) 32 and conjugates 4-9 was investigated by DLS. Figure 11 shows that POSS has the highest hydrodynamic diameter, which may suggest that its hydroxyl groups form a network of hydrogen bonds. The involvement of the POSS hydroxyl groups in the formation of ester bonds in conjugates 4-9 resulted in a reduction in their hydrodynamic diameter. 

Doxorubicin ( [18] . Hydroxyl functionalized silsesquioxane cage POSS(OH)32 was synthesized according to the method described previously in the literature [19] . The reproducibility of synthesized structures was proven by three independent experiments [17] . Syntheses of succinic anhydride-modified daunorubicin (SAMDAU) and succinic anhydride-modified doxorubicin were performed according to the methods described in the literature [16] (Figure S1 ).

Ultraviolet-visible (UV-Vis) measurements were carried out using the Specord S600 spectrophotometer using 10 mm path length quartz cuvettes. Solutions of conjugates at concentration Cconjugates = 0.05882 mg/mL were prepared in water/DMF (5:1). DOX/DAU release from the nanoconjugates was determined at a pH of 5.5 (citrate buffer solution-0.1 M) at 310 K (Table S3) . 1 H, 13 C, 1 H-13 C HSQC and DOSY nuclear magnetic resonance (NMR) spectra were recorded using Bruker Avance III 500 MHz instrument (Bruker BioSpin GmbH, Rhein- Gliwice, Poland) were purified as described in the literature [18] . Hydroxyl functionalized silsesquioxane cage POSS(OH) 32 was synthesized according to the method described previously in the literature [19] . The reproducibility of synthesized structures was proven by three independent experiments [17] . Syntheses of succinic anhydride-modified daunorubicin (SAMDAU) and succinic anhydride-modified doxorubicin were performed according to the methods described in the literature [16] (Figure S1 ).

Ultraviolet-visible (UV-Vis) measurements were carried out using the Specord S600 spectrophotometer using 10 mm path length quartz cuvettes. Solutions of conjugates at concentration C conjugates = 0.05882 mg/mL were prepared in water/DMF (5:1). DOX/DAU of the prodrug conjugates. The conjugates are larger in size, compared to anthracycline antibiotics themselves, which is favorable due to the presumably limited normal cell penetration during chemotherapy. In addition, they show longer release time, which makes them potential candidates for biomedical applications in anticancer therapy. POSS type nanocarriers were proven again [10, 11] to be useful systems in formation of nanoconjugates and nanocomplexes with anthracycline drugs. The present work shall be expanded by in vitro studies as soon as the test laboratory reopens after COVID-19 closure.

Supplementary Materials: The following are available online, Figure S1 : Scheme for the synthesis of SAMDOX and SAMDAU; Figure S2 : Scheme for the synthesis of POSSDAU-MR.; Figure S3 : Structure of POSSDAU-MR; Table S1 : NMR results for POSSDAU-MR.; Table S2 : Concentrations of the reagents used in conjugation reaction 4-9; Table S3 : Concentrations of the conjugates 4-9 in drugs release study; Figure S4 

310 K (Table S3)

and DOSY nuclear magnetic resonance (NMR) spectra were recorded using Bruker Avance III 500 MHz instrument (Bruker BioSpin GmbH, Rheinstetten, Germany)

FTIR (Fourier transform infrared spectroscopy) spectra were obtained using a Nico

) equipped with HeNe red laser

Reaction Synthesis of POSS T 8 [(CH 2 ) 2 S(CH 2 ) 2 OH] 8 . Octa(vinyl)silsesquioxane (T 8 -Vi) (2.00 g, 3.1593 × 10 −3 mol) and 2-mercaptoethanol (2.5 mL), 2,2-dimethoxy-2-phenylacetophenone (DMPA) (0.1295 g) were introduced into a quartz reactor and dissolved in THF (30 mL). residue was dissolved in THF (5 mL), precipitated in pentane (10 × 30 mL), separated, washed with pentane (100 mL) and dried under vacuum. Synthesis of POSSDAU-MR. The reaction carried out in the dark. SAMDAU, PEG1, NHS and EDC were placed in a flask, dissolved in DMF and stirred under nitrogen for new nanoconjugates were synthesized using polyhedral oligosilsesquioxanes (POSS) as nano-carriers for anthracyclines (DOX and DAU) and PEGs (water solubilizing agent). The new conjugates contain an ester bond capable of hydrolysis under the conditions of lowered pH (5.5), characteristic for cancer cells

Synthetic routes to nanomaterials containing anthracyclines: Noncovalent systems

Synthetic routes to nanoconjugates of anthracyclines

Anthracycline Nano-Delivery Systems to Overcome Multiple Drug Resistance: A Comprehensive Review

Dendrimer nanoparticles for colorectal cancer applications

Polymeric Nanocarriers of Drug Delivery Systems in Cancer Therapy

Anthracycline Chemotherapy and Cardiotoxicity. Cardiovasc. Drugs Ther

From Dose to Response: In Vivo Nanoparticle Processing and Potential Toxicity

In Vitro Studies of Polyhedral Oligo Silsesquioxanes: Evidence for Their Low Cytotoxicity

Unusual Enhancement of Doxorubicin Activity on Co-Delivery with Polyhedral Oligomeric Silsesquioxane (POSS)

Synthesis of the first POSS cage-Anthracycline conjugates via amide bonds

Reasons for enhanced activity of doxorubicin on co-delivery with octa(3-aminopropyl)silsesquioxane

The design and synthesis of an innovative octacarboxy-silsesquioxane building block

Cardiovascular application of polyhedral oligomeric silsesquioxane nanomaterials: A glimpse into prospective horizons

Towards establishing structure-activity relationships for mesoporous silica in drug delivery applications

Silsesquioxane-Based Nanoparticles Formed via Hydrolytic Condensation of Organotriethoxysilane Containing Hydroxy Groups

NMR analysis of antitumor drugs: Doxorubicin, daunorubicin and their functionalized derivatives

Hydrophilic polyhedral oligomeric silsesquioxane-POSS(OH) 32 as a complexing nanocarrier for doxorubicin and daunorubicin

The Preparation and Characterization of Amphiphilic Star Block Copolymer Nano Micelles Using Silsesquioxane as the Core

The financial support for this study was provided by the Centre of Molecular and Macromolecular Studies. K. Piorecka wishes to acknowledge the Preludium Grant UMO-2016/21/N/ST5/03360.

The authors declare no conflict of interest.Sample Availability: Samples of all compounds (POSS, SAMDAU, SAMDOX, compounds 4-9) are available from the authors.